These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women.
    Author: Maffei S, Mercuri A, Zucchelli GC, Vassalle C.
    Journal: Int J Cardiol; 2006 Feb 15; 107(2):194-9. PubMed ID: 16412796.
    Abstract:
    BACKGROUND: To evaluate whether the route of estrogen therapy (ET) may affect the levels of different vasoactive factors in healthy recent post-menopausal women. METHODS: We conducted a cross-over study in 20 healthy nonsmoking women in recent postmenopause (1.8+/-0.1 years). Women received either 1-month oral-ET (O-ET, 2 mg oral micronized 17beta estradiol daily) or transdermal-ET regimen (T-ET, 17beta estradiol 1.5 mg gel daily) with a 1-month wash-out interval. Blood pressure, plasma levels of endothelin-1 (ET), 6-ketoPGF1a (6-ketoPG, prostacyclin metabolite), nitrite/nitrate (NOx), epinephrine (E) and norepinephrine (NE) and lipid profile were measured at baseline and after each treatment. RESULTS: Both regimens significantly reduced E (p<0.01) and NE levels (p<0.05). O-ET reduced low-density lipoproteins (LDL) levels (p<0.05) and increased NOx values (p<0.01). Neither regimen caused significant changes of ET or 6-ketoPG. CONCLUSIONS: Our results, obtained in healthy women in recent menopause, indicate that the ratio between vasodilator (NOx and prostacyclin) and vasoconstrictor (ET) bioavailability shifted towards the previous ones after O-ET, while it remained unchanged after T-ET; moreover, catecholamines levels were reduced by both treatments already from 1 month of therapy. These changes might represent very early beneficial effects evoked by ET on the cardiovascular system.
    [Abstract] [Full Text] [Related] [New Search]